A Pulitzer Prize-winning weekly covering West Marin, including the towns of Point Reyes Station, Inverness, Bolinas, Stinson Beach, Marshall, Nicasio, Lagunitas, Woodacre, San Geronimo, Forest Knolls, ...

A Pulitzer Prize-winning weekly covering West Marin, including the towns of Point Reyes Station, Inverness, Bolinas, Stinson Beach, Marshall, Nicasio, Lagunitas, Woodacre, San Geronimo, Forest Knolls, ...

It looks like Eli Lilly’s oral selective estrogen receptor degrader (SERD) imlunestrant may need some extra help to reach a ...

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) today and set a price target of ...

An experimental drug stops advanced breast cancer from progressing in some people with tumors that have grown resistant to ...

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, ...

Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine ...

Olema presented Phase 1b/2 trial data for palazestrant combined with Novartis's Kisqali in ER-positive, HER2-negative breast ...

Novartis NVS announced positive top-line results from a late-stage study on Fabhalta (iptacopan) in adult patients with ...

Olema Pharmaceuticals shares rose 5.3% in premarket trading Monday after its investigational new drug application for OP-3136 was approved by the Food and Drug Administration. Shares were trading ...

Phase 1 clinical trial for OP-3136 to initiate in early 2025 SAN FRANCISCO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “”, Nasdaq: OLMA), a clinical-stage ...

"We are very pleased to have received notification from the FDA that OP-3136 may proceed into the clinic,” said David C. Myles, Ph.D., Chief Discovery and Non-Clinical Development Officer of Olema ...